Shares of Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) have earned a consensus rating of “Hold” from the twenty brokerages that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, five have issued a buy recommendation and one has […]
StockNews.com initiated coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Get Rating) in a report issued on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Several other equities research analysts have also commented on BPMC. VNET Group reiterated a maintains rating on shares of Blueprint Medicines in a research report on […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) – Equities research analysts at Zacks Research issued their Q2 2023 earnings per share (EPS) estimates for shares of Blueprint Medicines in a research note issued to investors on Monday, May 15th. Zacks Research analyst A. Chakroborty expects that the biotechnology company will earn ($2.70) per share for […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 3,800,000 shares, a decline of 11.8% from the April 15th total of 4,310,000 shares. Based on an average daily trading volume, of 596,800 shares, the short-interest ratio […]
Blueprint Medicines Co. (NASDAQ:BPMC – Get Rating) was the recipient of a large decrease in short interest in April. As of April 30th, there was short interest totalling 3,800,000 shares, a decrease of 11.8% from the April 15th total of 4,310,000 shares. Based on an average daily volume of 596,800 shares, the days-to-cover ratio is […]